Intervention

Lenacapavir Tablet

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting2

Common conditions3

Lead sponsors shown1

Clinical trials

6 shown

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961 · 2026-07-14

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778 · 2026-03-17

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716 · 2025-07-22

ACTIVE_NOT_RECRUITING

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · 2024-10-07

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · 2023-12-13

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · 2023-11-17

ACTIVE_NOT_RECRUITING

Common conditions

Pre-Exposure Prophylaxis of HIV Infection3 HIV Infections2 HIV Pre-exposure Prophylaxis1

Leading sponsors

Gilead Sciences6

Trial status mix

ACTIVE_NOT_RECRUITING4

RECRUITING2

Phase mix

PHASE23

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.